Export

Levodopa + carbidopa
Essential medicine status
General description
Levodopa + carbidopa is a combination of L-Dopa and a peripheral decarboxylase inhibitor used to treat Parkinson disease.
INN
Levodopa + carbidopa
Medicine type
Chemical agent
EML status history
First added in 1977 (TRS 615) for Parkinson disease
Therapeutic equivalent for
Recommendations
Section
Antiparkinsonism medicines
  • Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet